Global Muscle Relaxant Drugs Market is valued at USD 4.37 Billion in 2021 and expected to reach USD 6.43 Billion by 2028 with a CAGR of 5.70% over the forecast period.
Global Muscle Relaxant Drugs Market: Global Size, Trends, Competitive, Historical & Forecast Analysis, 2021-2028- Increasing in back problems and health issues associated with older generation are key driving factors for the growth of Global Muscle Relaxant Drugs Market.
The Muscle Relaxant Medications are used to relive the muscle pains often known as muscle spasms. This condition is related to or directly affects the nervous system. Other associated conditions are motor neuron disease, cerebral palsy and multiple sclerosis. Moreover, muscle spasms can result into head or back long term difficulties. It is recommended to obtain these drugs on doctor’s prescription as they have potential to reduce the spasm and stress of the muscles. Since, these drugs make the central nervous system to slow down, they are considered to be suitable for younger adult generation. The patients with other medical problems like liver, kidney or heart diseases should avoid taking these relaxant drugs which may result into other side effects. Muscle relaxant drugs are considered to be addictive hence it should be taken with precautions and for short period of time. Also it is highly advised to keep them away from children and other adults.
Increasing prevalence of lower back pain with surge in number of surgeries in geriatric population as well as rising healthcare expenditures of relaxant drugs are expected to boost the growth of muscle relaxant drugs market over forecast period.
The regions covered in this Global Muscle Relaxant Drugs Market report are North America, Europe, Asia-Pacific and Rest of the World. On the basis of country level, the market of Medical Tourism is sub divided into U.S., Mexico, Canada, U.K., France, Germany, Italy, China, Japan, India, South East Asia, Middle East Asia, Africa, etc.
Some major key players for Global Muscle Relaxant Drugs Market are Pfizer Inc., F.Hoffmann-La Roche Ltd, Galderma S.A., Intas Pharmaceuticals Ltd., Johnson & Johnson, Merck & Co. and others.
Rising prevalence of musculoskeletal problems and growing awareness amongst the consumers regarding their treatment and management are expected to be the dynamic factors behind the growth of global market of muscle relaxant drugs. According to the World Health Organization (WHO), the non-specific burden of lower back pain has been increased substantially around the globe which is estimated at 60–70% in industrialized countries whereas one-year prevalence increasing rate 15–45%, adult incidence 5% per year and mostly occurrence of LBP has seen in above 35 age group people. However, severe side effects related to muscle relaxant drugs such as habituation and respiratory arrest will restrict the growth of global muscle relaxant drugs market. The recent technologically improved muscle relaxants are structurally distinct drugs prescribed for reducing muscle spasms, pain, and hyperreflexia. Centrally acting skeletal muscle relaxants are manufactured by various pharmaceutical companies with variable price. The present study, aimed to analyze the cost variation of various brands of centrally acting skeletal muscle relaxants, so as to help the physician to choose the cost effective treatment to drive the market growth.
News: Long term Use of Muscle Relaxant has skyrocketed since 2005
June 25, 2020; According to Perelman School of Medicine, researchers reported that the usage of relaxant drugs tripled in 2016 from 2005. They also observed that around 70% patients were prescribed relaxants drugs having opioid combination, consider causing dangerous interactions. They also reported that these drugs were prescribed to elderly patients which should always be avoided as per the national guidelines. These results were published in JAMA Network Open.
The major factor driving the growth of global Muscle Relaxant Drugs market is rising prevalence of chronic back problems followed by the surge in geriatric population prone to muscle pain or spasm. According to World Health Organization (WHO), back pain patients have been estimated to increase from 60% to 70% in major countries. The U.S. Food and Drug Administration are against the usage of muscle relaxants and opioids together as this combination can cause some issues. But doctors still prescribe these medications as there are no alternatives available. This factor can be considered as driving agent to the market. The long term usage of these drugs can result to some potential side effects like drowsiness, headache, fatigue and others. These drugs are restricted for the patients having liver, kidney and heart disease as well as stringent regulatory policies for approval are likely to hamper the growth of muscle relaxant drugs market. on the other hand, surge in R&D activities for the development of novel drugs along with FDA approvals and strategic collaborations in the market is expected to create opportunities.
North America is expected to dominate the global Muscle Relaxant Drugs market over the forecast period attributed to the rising number of surgical procedures couple with high disposable income. Moreover, high prevalence rate of chronic back supported by the presence of huge geriatric population in this region. For example; World Health Organization reported that America has more than 50% aging population followed by Asia Pacific. Asia Pacific is expected to develop at a significant rate over the forecast period owing to the development in healthcare infrastructure. Furthermore, better accessibility to healthcare facilities followed by the launch of generic formulations and geographical expansion by key market players. All the above mentioned factors is expected to augment the growth of muscle relaxant drugs market.
|2018 - 2020
|2021 - 2028
|Market Size in 2020:
|USD 4.37 Billion
|Base year considered
|Forecast Period CAGR %:
|Market Size Expected in 2028:
|USD 6.43 Billion
|Tables, Charts & Figures:
|Pfizer Inc., F.Hoffmann-La Roche Ltd, Galderma S.A., Intas Pharmaceuticals Ltd., Johnson & Johnson, Merck & Co. and others
|By Product Type, By Application Type
|North America, U.S., Mexico, Canada, Europe, UK, France, Germany, Italy, Asia Pacific, China, Japan, India, Southeast Asia, South America, Brazil, Argentina, Columbia, The Middle East and Africa, GCC, Africa, Rest of the Middle East and Africa
Key Benefits for Global Muscle Relaxant Drugs Market Report:
Global Muscle Relaxant Drugs Market report is segmented on the basis of type, application and region & country level. Based upon drug type, global Muscle Relaxant Drugs market is classified into skeletal muscle relaxants, neuromuscular blockers, centrally acting muscle relaxants, direct acting muscle relaxants and others. Based upon the application, global muscle relaxant drugs market is classified into Retail Pharmacy, Hospital Pharmacy and Online Pharmacy.
By Product Type:
By Application Type:
Middle East and Africa
We are always looking to hire talented individuals with equal and extraordinary proportions of industry expertise, problem solving ability and inclination interested? please email us email@example.comJOIN US
BrandEssence® Market Research and Consulting Pvt ltd.
124, City Road, London EC1V 2NX
© Copyright 2024-25 BrandEssence® Market Research and Consulting Pvt ltd. All Rights Reserved | Designed by BrandEssence®